Facilitated, small-group discussions. Interactive participation leads to problem-solving solutions and future collaborations around focused topics.
What’s the BuzZ about?
PepTalk’s BuzZ Sessions are focused, stimulating discussions in which delegates discuss important and interesting topics related to upstream protein expression and production through downstream scale-up and manufacturing. This is a moderated discussion with brainstorming and interactive problem-solving between scientists from diverse areas who share a common interest in the discussion topic.
These are forums for open discussion of protein-related challenges, and not sales opportunities. We emphasize that these breakout groups are for interactive discussions among scientists and are not meant to be, in any way, a corporate or product discussion. Topics can be limited to one protein area or may address issues which cross over the borders between pipeline meeting topics. Moderators should be well-versed in the topic area and able to keep the discussion focused and productive.
Due to popular demand, we’ll host two BuzZ Session times this year. All BuzZ Sessions will be located in the Atlas Ballroom on Tuesday, January 20. Session A will be held 2:00-3:00 pm and Session B 3:45-4:45 pm.
To submit a BuzZ Session topic for consideration, please click here.
Protein Therapeutic Immunogenicity and T Cell Epitopes
Ronit Mazor, Ph.D., Research Fellow, Lab for Molecular Biology (LMB), NCI/NIH
Site-Specific Bioconjugations of Proteins
Oliver Thiel, Ph.D., Principal Scientist, Chemical Process Research & Development, Amgen, Inc.
De novo Discovery or Engineering? – Choice to Derive Stable Single Chain Fv for Bispecific Antibody Engineering
Yang Shen, Ph.D., Research Advisor, Antibody Engineering, Antibody Technology, ImClone Systems, A Wholly-Owned Subsidiary of Eli Lilly & Company
Two Decades of Different Ways to Improve Biologics – What Is the (Clinical) Outcome?
Manfred Schuster, Ph.D., COO, Apeiron Biologics AG
Enzyme Therapeutics: Challenges for Monitoring, Improving and Preserving Catalytic Activities
Manfred Konrad, Ph.D., Head of Enzyme Biochemistry Laboratory, Max Planck Institute for Biophysical Chemistry
Protein Therapeutics for Eye Diseases: The Best Targets and Diseases
Eric Furfine, Ph.D., CSO, Eleven Biotherapeutics
The Future Application of Hybridomas, Natural Libraries, Synthetic Libraries, Humanizations, Transgenics and Alternative Scaffolds in mAb Discovery and Engineering
Jacob Glanville, Ph.D., CSO, Distributed Bio
Unusual Antibody Scaffolds
Vaughn Smider, M.D., Ph.D., Assistant Professor, Molecular Biology, The Scripps Research Institute
Using a Recombinant Antibody Platform for the Generation of Therapeutic Antibodies
Michael Hornsby, Ph.D. Researcher, Pharmaceutical Chemistry, University of California, San Francisco
Marcin Paduch, Ph.D., Technical Director, Synthetic Antibody & Crystallography Core Facility, The University of Chicago
Assay Formats for Testing Protein-Protein Interactions
Jonas V. Schaefer, Ph.D., Head, High-Throughput Laboratory, Department of Biochemistry, University of Zurich
Multi-Epitope Targeting Antibodies: How to Select between Mixtures and Different Bispecific Antibody Formats
John Haurum, M.D., D.Phil., CEO, F-star GmbH and F-star Biotechnology Ltd.
The Future Direction of Immune Checkpoint Inhibitors
Gregory P. Adams, Ph.D., Director of Biological Research and Therapeutics, Fox Chase Cancer Center
What to Do about Sequence Liabilities in Antibody Therapeutics: When to Intervene and How Best to Assess and Address Them
Melissa Damschroder, Ph.D., Associate Director, Research & Development, Antibody Discovery and Protein Engineering, MedImmune
Accelerated Routes to High-Quality Target Validation Molecules: Necessary or Not?
William “Jonny” Finlay, Ph.D., Director, Pfizer, Inc.
Sites and Insights: Generalizing Insights from Site-Specific Features of Tumor Therapy
Lois Lampson, Ph.D., Associate Professor of Surgery, Brigham and Women’s Hospital
Manipulating the Tumor Microenvironment to Improve Antibody Therapy
Stephen Beers, Ph.D., Senior Research Fellow, Faculty of Medicine, University of Southampton
Developability Assessment for Drug Product Candidates
Deniz Temel, Ph.D., Postdoctoral Researcher, Technical Development, Biogen Idec
High-Throughput Screening in Formulation Development
Lisa A. Kueltzo, Ph.D., Staff Scientist, Formulation Development, Vaccine Production Program Laboratory, National Institutes of Health
Balancing Act of Electrostatics vs. Hydrophobicity in Proteins
Murali Bilikallahalli, Ph.D., Associate Director, Formulation Sciences, Proteins, Vaccines & Oligos, MedImmune
Considerations in Early Formulation Development
Tom Spitznagel, Ph.D., Vice President, Development, MacroGenics, Inc.
Developing a Stable Lyophilized Biologic Formulation
Petteri Heljo, Ph.D., Postdoctoral Researcher, Early Stage Pharmaceutical Development, F. Hoffmann-La Roche
Challenges in Formulation Development
Malgorzata Tracka, Scientist II, Formulation Sciences, MedImmune
Method Transfer and Validation: Challenges and Lessons Learned in the Transfer of Formulation or Analytical Methods between Labs
David Burkhart, Ph.D., Investigator, GlaxoSmithKline Biologicals
Lyophilization Process Scale-Up and Transfer
Serguei Tchessalov, Ph.D., Associate Research Fellow, Biotherapeutics Pharmaceutical Research & Development, Pfizer, Inc.
Is Nucleation Control a Viable Option for Biopharmaceutical Companies?
Timothy R. McCoy, MSc, Principal Scientist, Technical Development, Genzyme Ireland
How to Develop a Robust Lyophilized Combination Product in Dual Chamber Syringes/Cartridges?
Bingquan (Stuart) Wang, Ph.D., Senior Scientist, Protein Formulation Development, Biogen Idec
Lyophilization of Biologics above the Glass Transition Temperature (Tg’)
Mark Yang, Ph.D., Director, Fill Finish Development, Commercial Process Development, Genzyme, a Sanofi Company
Use of Surrogates for Lyophilization Process Design, Development and Scale-Up
Sajal M. Patel, Scientist II, Formulation Sciences, MedImmune, Inc.
DNA Mutant Library Creation for Protein Engineering Applications
Elad Firnberg, Ph.D., President and Co-Founder, Revolve Biotechnologies, Inc.
Lift Off: Integrated Launch of a New Biotech Company, from Technology to Team to Launch to Exit Plan
Joseph Kittle, Jr., Ph.D., Assistant Professor, Chemistry and Biochemistry, Ohio University and CSO, Molecular Technologies Laboratories, LLC
Synthetic Biology Infrastructure for Protein-Related Applications
Ilias Tagkopoulos, Ph.D., Assistant Professor, Computer Science and Genome Center, University of California, Davis
Cheemeng Tan, Ph.D., Assistant Professor, Biomedical Engineering, University of California, Davis
Challenges of Expression of Difficult Proteins: New Solutions
James D. Love, Ph.D., Director, Technology Development, Biochemistry, Albert Einstein College of Medicine
Is Clone Stability an Issue for Either Cell Banking or Long Production Processes?
Zhimei Du, Ph.D., Principal Scientist, Cell Culture Development & Manufacturing, Teva Pharmaceuticals USA
Understanding Product Quality Attribute Robustness during Clone Screening and Small-Scale Process Development
Shivani Gupta, Ph.D., Associate Scientist, Cell Line Development, Amgen, Inc.
Next-Generation Expression Platforms and Production of Complex Multiple Domain Proteins
Miller Tran, Ph.D., Senior Scientist, Lead Discovery, Verdant Therapeutics, Inc.
The Messenger: The Importance of RNA Biology in Recombinant Expression
Thomas Kallehauge, Ph.D., Research Scientist, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
Using -Omics for Protein Expression Enhancement – Exciting Opportunities, Practical Applications and Realistic Expectations for High-Content Data
Nathan E. Lewis, Ph.D., Assistant Professor, Lab of Systems Biochemistry and Cell Engineering, University of California, San Diego
Expanding the Role of Transient Gene Expression
James Brady, Ph.D., MBA, Director, Technical Applications, MaxCyte, Inc.
Common Issues with Transient Protein Production
Richard Altman, MS, Research Scientist, Molecular Sciences, Alexion Pharmaceuticals
Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.
Krista Johnson, MSc, Research Scientist, Protein Sciences, Alexion Pharmaceuticals
Challenges and Strategies in Analytical Characterization to Support Research and Development of Novel Biotherapeutics
Qiong (Joan) Guo, Ph.D., Senior Principal Scientist & Analytical Group Leader, Vaccine Immunotherapeutics Research Unit, Pfizer, Inc.
The Challenge of Characterizing Molecules and Defining Comparability with Assays that Provide Either Too Much or Too Little Quantitative Data Output
Juma Bridgewater, Ph.D., Scientist III, Analytical and Pharmaceutical Sciences, ImmunoGen, Inc.
Role of Platform Analytics in Accelerating Early Stage Development
Nomalie Jaya, Ph.D., Senior Scientist, Analytical Biochemistry, Seattle Genetics, Inc.
Multivariate Analysis (MVA) in Biologics Development
Vishal C. Nashine, Ph.D., Senior Research Investigator, Drug Product Science & Technology, Bristol-Myers Squibb Co.
Containment/Delivery Systems Affecting Proteins
Diane Paskiet, Ph.D., Director, Scientific Affairs, West Pharmaceutical
High-Throughput Analytical Development to Support Bioprocess Monitoring
Xiaodun (Susan) Mou, Ph.D., Associate Principal Scientist , BTE, Merck & Co., Inc.
Mitigation of Protein Fouling on Surfaces
Shyam V. Vaidya, Ph.D., Principal R&D Scientist, Abbott Laboratories
Controlling Protein Solubility and Viscosity
Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
Anticipating Early Stability Issues: Characterization Methods to Detect Aggregation Propensity
Joël Richard, Ph.D., Senior Vice President, Peptides, Head of CMC Dreux Site, Ipsen
Characterization of Subvisible and Visible Particles in Biopharmaceutical Products
Andrea Hawe, Ph.D., Chief Scientific Officer, Coriolis Pharma
Protein Aggregates: Adding Light Scattering to Obscuration for Wide-Range (0.15-200 µm) Particle Counting and Sizing
David F. Nicoli, Ph.D., Vice President R&D, Particle Sizing Systems, LLC
Driving the Implementation of Continuous Processing Enabled by Single-Use
David Pollard, Ph.D., Executive Director, Bioprocess Development, Merck Research Laboratories, Merck & Co., Inc.; Member, BioPhorum Operations Group (BPoG)
Management of Leachables & Extractables-Related Risk in Processes with Single-Use Components
Naveen Pathak, MSc, Director, MS&T, Process Development & Manufacturing Science, Shire
Challenges to the Norm - New and Innovative Ways to Purify CHO Proteins Using None-Standard Processes which Challenge the Protein A Standard
Adam Goldstein, MS, Senior Manager, Technical Operations, Genentech, Inc.
Standardization of Single-Use Designs and Practices
Jerold Martin, MSc, Chairman, Technology Committee, BPSA and Senior Vice President, Global Scientific Affairs, Pall Life Sciences
Manufacturing and Economic Considerations for Implementing Single-Use and Continuous Processing
Robert Dream, PE, CPIP, CPMP, Ph.D., Principal, HDR Company Ltd.
Incorporating Process Control, Automation and PAT in the Design of a Continuous, Single-Use Facility
Jørgen Magnus, Ph.D., Manager, R&D, Bayer Technology Services GmbH
Reproducing Irreproducible Results
Mario Lebendiker, Ph.D., Head, Protein Purification Facility, Hebrew University of Jerusalem
Purification of Therapeutic Proteins Derived from Antibody Fragments (e.g., Bispecific Antibodies and Fab'2)
Julie Q. Hang, Ph.D., Senior Scientist, Protein Chemistry, Genentech, Inc.
Comparability or Identity?
Carlo Zambonelli, Ph.D., Senior Scientist and Head, Biophysics, Novartis Vaccines and Diagnostics
Purification of Membrane Proteins: Challenges and Approaches
Alexei Yeliseev, Ph.D., Staff Scientist, NIAAA, NIH